POMC, proopiomelanocortin, 5443

N. diseases: 873; N. variants: 39
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030193
Disease: Pain
Pain
0.400 Biomarker phenotype BEFREE In this study, we report that α-MSH suppresses the transient outward A-type K<sup>+</sup> current (<i>I</i><sub>A</sub>) in trigeminal ganglion (TG) neurons and thereby modulates neuronal excitability and peripheral pain sensitivity in rats. 30745360 2019
CUI: C0030193
Disease: Pain
Pain
0.400 AlteredExpression phenotype BEFREE Compared with non-LIFU groups, β-endorphin levels and pain thresholds were significantly increased (P < .05), whereas nuclear factor- κB messenger RNA, prostaglandin E<sub>2</sub> , interleukin- 1β, and 5-hydroxytryptamine levels were significantly reduced (P < .05) after LIFU treatment in rabbits with STI. 31785024 2019
CUI: C0030193
Disease: Pain
Pain
0.400 AlteredExpression phenotype BEFREE Regression analyses indicated that β-endorphin level was negatively related to pressure pain threshold (β = -17.18, <i>p</i> = .02) and positively related to punctate mechanical pain (β = 17.13, <i>p</i> = .04), after controlling for age, gender, and OA severity. 31146541 2019
CUI: C0030193
Disease: Pain
Pain
0.400 Biomarker phenotype BEFREE Advancements in β-endorphin measurements may help us better quantify pain intensity. 30256990 2019
CUI: C0030193
Disease: Pain
Pain
0.400 AlteredExpression phenotype BEFREE The role of Oxycontin was analyzed by collecting the patients' general information, age, gender, Karnofsky performance status (KPS) score, site of pain and degree of pain, and by detecting the remission rates of clinical symptoms, average analgesic time, number of pain outbreak per day, levels of β-EP, CGRP and PGE2, as well as changes of KPS score, Zubrod performance status (ZPS) score and quality of life (QoL) score of the enrolled patients before treatment and at 1 week afer treatment. 30570885 2019